Full-Time

Computational Clinical Scientist II

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$120k - $158kAnnually

Mid

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Bioinformatics
Genomics
Biology & Biotech
Required Skills
Python
Data Science
R
Requirements
  • MS. or Ph.D. in bioinformatics, biology, data science or a related field with emphasis on biological data analysis
  • 2+ years of pharmaceutical or biotech experience in bioinformatics focused on oncology, immunology, or related field
  • Proficiency and experience programming using R and/or Python
  • Proficiency in statistical models and analysis of clinical data. Some ML experience a strong plus.
  • Proficiency in visualizations and faceting of molecular data necessary (oncoplots, heatmaps, PCA, etc.)
  • Experience with efficacy, baseline demographic, and other outcome data generated in a clinical trial
  • Experience with statistical methods i.e. survival analysis, and causal inference
  • Expertise in bioinformatic analysis of cancer signaling pathways and driver mutations
  • Experience in tools to analyze cancer genomics data types (RNA, WES, ctDNA, etc) and common tool outputs (GATK, Salmon, OncoKB, VEP, etc.) preferred
Responsibilities
  • Integrate multiple data sources including circulating tumor DNA, patient enrollment data, molecular profiling (RNA/DNA sequencing outputs), multiplex immunohistochemistry to identify and validate new biomarkers for candidate drugs
  • Work with internal groups, contract research organizations and collaborators to deliver validated biomarker data and analysis
  • Support the development of biomarker related aspects of the trial design where bioinformatic analysis is required, including study protocols, lab manuals, clinical study reports, and other regulatory documents
  • Work with biomarker scientists to support analysis of biomarker readouts (summary statistics, and visualization of efficacy in molecular subgroups)
  • Collaborate with preclinical bioinformaticians to design, analyze and interpret experiments to validate biomarkers, understand compound mechanism of action, and identify biomarkers for patient selection and target engagement

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, which target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Increased interest in targeted therapies boosts investment and partnership opportunities.
  • Shift towards personalized medicine aligns with their focus on genetic mutations.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and delay timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' market strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive licensing with the University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?